CpG island methylator phenotype in plasma is associated with hepatocellular carcinoma prognosis

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 42

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

383

HTML

3836

Tables (1-4)

248

Sum=4467

Nov 14, 2011 (publication date) through Dec 30, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Nov 14, 2011; 17(42): 4718-4724
Published online Nov 14, 2011. doi: 10.3748/wjg.v17.i42.4718

Table 4 Relationship between CpG island methylator phenotype and prognosis of hepatocellular carcinomas after a one-year follow-up (n = 98)

¹Indicates χ² test comparing the prognosis between CIMP+ and CIMP- in tumor tissues; ²Indicates the comparison in the plasma.

^aP < 0.05. CIMP: CpG island methylator phenotype.

Citation: Liu JB, Zhang YX, Zhou SH, Shi MX, Cai J, Liu Y, Chen KP, Qiang FL. CpG island methylator phenotype in plasma is associated with hepatocellular carcinoma prognosis. World J Gastroenterol 2011; 17(42): 4718-4724
URL: https://www.wjgnet.com/1007-9327/full/v17/i42/4718.htm
DOI: https://dx.doi.org/10.3748/wjg.v17.i42.4718